Neoadjuvant abiraterone acetate plus leuprolide acetate in localised high-risk prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer.

Share this video